It seems that it’s all over for Canntrust Holdings (TSX: TRST) (NYSE: CTST) shareholders. The company confirmed within a news release last night that its equity will be delisted from the major exchanges, and that a cease trade order will remain on the equity.
The delisting, which was all but previously confirmed by the company when it announced that it had obtained creditor protection, is now official. On March 31, the company received a notice from the New York Stock Exchange that the trading of the firms common shares were suspended. An application to the Securities and Exchange Commission is currently pending for the full delisting of the equity. The application is subjection to the completion of applicable procedures.
Much more clarity exists around the firms Toronto Stock Exchange listing, where the equity will be removed from the exchange at the close of market on May 6, 2020. Additionally, the Ontario Securities Commission has advised the company that it would be seeking a cease trade order against the company to prevent trading in the common shares on any exchange in Canada.
The measure by the OSC is a result of the firm obtaining creditor protection, its failure to file required regulatory filings, and its pending delistings from major exchanges.
The only bright side for the company is that it has received partial relief from Health Canada. Canntrust will be allowed to propagate what is referred to as “Mother Plants” at its Niagara facility, indicating that there is a chance that the full suspension may soon be lifted.
Canntrust Holdings last traded at $0.91 on the TSX. It has been halted since March 31, 2020. Canntrust reportedly has a cash position of $140 million as of March 31.
Information for this briefing was found via Sedar and CannTrust Holdings Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.